GALECTIN THERAPEUTICS INC — Director's Dealing 2019

Jun 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-05-31

Reporting Person: FREEMAN KEVIN D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-31	Common Stock	P	7710	$4.28	Acquired	9710	Indirect
2019-05-31	Common Stock	P	1426	$4.28	Acquired	23469	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-31	Common Stock Purchase Warrant (right to buy)	$7.00	P	4753	Acquired	2026-05-31	Common Stock (356)	Direct
2019-05-31	Common Stock Purchase Warrant (right to buy)	$7.00	P	25700	Acquired	2026-05-31	Common Stock (1928)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	16000	Indirect

Footnotes

F1: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company.